Device Trial Radar · NCT02809690
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Sep 12, 2016
Primary completion
Jul 21, 2021
Study completion Jul 21, 2021
Sponsor
- Lead sponsor
- University of Southern CaliforniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI); National Institute for Biomedical Imaging and Bioengineering (NIBIB)
- First posted
- Jun 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.
Conditions
- Prostate Neoplasm
Interventions
CATDevice
Undergo 18F-FMAU PET/CT
18F-FMAUDrug
Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
Laboratory Biomarker AnalysisOther
Correlative studies
Multiparametric Magnetic Resonance ImagingProcedure
Undergo mpMRI
Positron Emission TomographyDevice
Undergo 18F-FMAU PET/CT
UltrasoundDevice
Undergo TRUS-guided biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of men for whom biopsy cores taken based only on the 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core or the mpMRI-directed prostate biopsiesTime frame: Up to 1 year
- Proportion of men for whom the 18F-FMAU PET/CT identified all lesions that were found to have cancer based on the standard TRUS-guided and the mpMRI directed core prostate biopsiesTime frame: Up to 1 year
- Proportion of men who completed both imaging procedures and for whom biopsy cores taken based only on the fluorine 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core prostate biopsiesTime frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.